Comparison of 18F–FDG PET/MRI and MRI alone for whole-body staging and potential impact on therapeutic management of women with suspected recurrent pelvic cancer: a follow-up study

[1]  P. Pandharipande,et al.  ACR Appropriateness Criteria® Staging and Follow-Up of Ovarian Cancer. , 2013, Journal of the American College of Radiology : JACR.

[2]  A. Wetter,et al.  PET/MR imaging of pelvic malignancies. , 2017, European journal of radiology.

[3]  Gerald Antoch,et al.  Evaluation of 68Ga-DOTATOC PET/MRI for whole-body staging of neuroendocrine tumours in comparison with 68Ga-DOTATOC PET/CT , 2017, European Radiology.

[4]  Lino Morris Sawicki,et al.  Whole-body staging of female patients with recurrent pelvic malignancies: Ultra-fast 18F-FDG PET/MRI compared to 18F-FDG PET/CT and CT , 2017, PloS one.

[5]  F. De Keyzer,et al.  Whole-body diffusion-weighted magnetic resonance imaging in the diagnosis of recurrent ovarian cancer: a clinical feasibility study. , 2016, The British journal of radiology.

[6]  J. Czernin,et al.  18F-FDG PET/CT and PET/MRI Perform Equally Well in Cancer: Evidence from Studies on More Than 2,300 Patients , 2016, The Journal of Nuclear Medicine.

[7]  V. Lavoué,et al.  [Curative pelvic exenteration for recurrent cervical carcinoma in the era of concurrent chemotherapy and radiation therapy. A systematic review]. , 2016, Journal de gynecologie, obstetrique et biologie de la reproduction.

[8]  Michael Forsting,et al.  Implementation of FAST-PET/MRI for whole-body staging of female patients with recurrent pelvic malignancies: A comparison to PET/CT. , 2015, European journal of radiology.

[9]  Michael Forsting,et al.  Simultaneous Positron Emission Tomography/Magnetic Resonance Imaging for Whole-Body Staging in Patients With Recurrent Gynecological Malignancies of the Pelvis: A Comparison to Whole-Body Magnetic Resonance Imaging Alone , 2014, Investigative radiology.

[10]  C. Ahlin,et al.  Natural history of recurrences in endometrial carcinoma , 2014, Oncology letters.

[11]  H. Pannu,et al.  ACR Appropriateness Criteria® pretreatment evaluation and follow-up of endometrial cancer. , 2014, Ultrasound quarterly.

[12]  M. Forsting,et al.  [18F]FDG PET/MRI vs. PET/CT for whole-body staging in patients with recurrent malignancies of the female pelvis: initial results , 2014, European Journal of Nuclear Medicine and Molecular Imaging.

[13]  Sokbom Kang,et al.  Pelvic exenteration for recurrent cervical cancer: ten-year experience at National Cancer Center in Korea , 2012, Journal of gynecologic oncology.

[14]  N. Avril,et al.  The role of FDG-PET/CT in gynaecological cancers , 2012, Cancer imaging : the official publication of the International Cancer Imaging Society.

[15]  J. Thigpen.  Management of recurrent cervical cancer: A review of the literature , 2012 .

[16]  J. Berek,et al.  Predictors of survival in patients with recurrent ovarian cancer undergoing secondary cytoreductive surgery based on the pooled analysis of an international collaborative cohort , 2011, British Journal of Cancer.

[17]  J. Rauh-Hain,et al.  Treatment for advanced and recurrent endometrial carcinoma: combined modalities. , 2010, The oncologist.

[18]  Byung Il Kim,et al.  Detection of Recurrence by 18F-FDG PET in Patients with Endometrial Cancer Showing No Evidence of Disease , 2010, Journal of Korean medical science.

[19]  A. Rockall,et al.  MRI and PET Scans for Primary Staging and Detection of Cervical Cancer Recurrence , 2010, Women's health.

[20]  Xu Zhang,et al.  [Application of 18F-FDG PET/CT in cervical cancer with elevated levels of serum squamous cell carcinoma antigen during the follow-up]. , 2009, Ai zheng = Aizheng = Chinese journal of cancer.

[21]  E. Mittra,et al.  Efficacy of 18F-FDG PET/CT in the evaluation of patients with recurrent cervical carcinoma , 2009, European Journal of Nuclear Medicine and Molecular Imaging.

[22]  Gang Huang,et al.  CA 125, PET alone, PET-CT, CT and MRI in diagnosing recurrent ovarian carcinoma: a systematic review and meta-analysis. , 2009, European journal of radiology.

[23]  K. Sugimura,et al.  Performance of integrated FDG-PET/contrast-enhanced CT in the diagnosis of recurrent uterine cancer: comparison with PET and enhanced CT , 2009, European Journal of Nuclear Medicine and Molecular Imaging.

[24]  N. Avril,et al.  Clinical use of combined positron emission tomography and computed tomography (FDG-PET/CT) in recurrent ovarian cancer. , 2007, Gynecologic oncology.

[25]  A. Fischman,et al.  PET–CT vs. CT alone in ovarian cancer recurrence , 2007, Abdominal Imaging.

[26]  V. Bettinardi,et al.  Post-therapy surveillance of patients with uterine cancers: value of integrated FDG PET/CT in the detection of recurrence , 2007, European Journal of Nuclear Medicine and Molecular Imaging.

[27]  H. Chung,et al.  Clinical impact of FDG-PET imaging in post-therapy surveillance of uterine cervical cancer: from diagnosis to prognosis. , 2006, Gynecologic oncology.

[28]  T. Miyamoto,et al.  Whole-body positron emission tomography and tumor marker CA125 for detection of recurrence in epithelial ovarian cancer , 2005, International Journal of Gynecologic Cancer.

[29]  E. Hauth,et al.  Evaluation of integrated whole-body PET/CT in the detection of recurrent ovarian cancer. , 2005, European journal of radiology.

[30]  Patrick M M Bossuyt,et al.  Computed tomography and magnetic resonance imaging in staging of uterine cervical carcinoma: a systematic review. , 2003, Gynecologic oncology.

[31]  M. Friedlander,et al.  Guidelines for the treatment of recurrent and metastatic cervical cancer. , 2002, The oncologist.

[32]  E. Salom,et al.  Recurrent vulvar cancer , 2002, Current treatment options in oncology.

[33]  A. Gadducci,et al.  Patterns of recurrence in patients with squamous cell carcinoma of the vulva , 2000, Cancer.

[34]  T C Randall,et al.  Ten-year follow-up of ovarian cancer patients after second-look laparotomy with negative findings. , 1999, Obstetrics and gynecology.